QualityDipStocks / Real Estate · REITs
Diversified Healthcare Trust of Beneficial Interest DHC
Outside our quality screen, so we don’t track its dips. It’s 20% below its 52-week high.
Outside our quality screen. No fair value estimate for now: its free cash flow is negative.
- Fair value est.
- n/a
- Market Value
- $7.95price −3%
- Off 52-wk high
- −20%
- Risk vs market
- Lowbeta 0.57
52-week range 65% of the way from its 52-week low to its high
Price $7.74Market Value $7.95
1 bullish · 5 bearish See why
Repriced or dip?
Mixed signals
The price is 20% below its 52-week high (Jul 21), but the business held up: net cash (cash minus debt) −0.5% of market cap since the high.
Some numbers held up (net cash (cash minus debt) −0.5% of market cap since the high), others slipped (revenue growth rate −4.2 pts, revenue −2.5%). The price is 20% below its 52-week high.
The price is 20% below its 52-week high, and the business changed too: revenue growth rate −4.2 pts, revenue −2.5%.
Within 10% of its 52-week high, so there is no dip to judge yet.
The evidence 6 numbers, high vs now
- Revenue, last 12 months$1.5B → $1.5B (−2.5%)changed
- Revenue growth rate+0.4% → −3.8% a year (−4.2 pts)changed
- Shares outstanding+2.0% (more shares, each owns less)about the same
- Net cash (cash minus debt)−0.5% of market cap since the highheld up
- Stock vs its sector (Real Estate)stock −20%, sector median −7% since Jul 21about the same
- Price fall vs business numbersprice −20%, revenue/EPS/FCF median −3% (shown, not scored)
Business numbers as reported at the high (12 months to Mar 31, 2026) vs the latest filing (12 months to Sep 30, 2026). Each measure is scored from −1 (business changed) to +1 (business intact) and weighted: revenue, earnings per share, free cash flow, operating margin, revenue growth rate, share count, net cash and the move vs its sector. 60 or more reads as a dip, 40 or less as a repricing. Analyst estimates are not in our data, so they are not used. How to read it
Data-based read, not advice.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for DHC: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much DHC moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves much less than the market, but its own price swings are 3.0× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.57
- Volatility
- 38% vs 13% SPY
- Correlation SPY
- 0.19
- Correlation QQQ
- 0.14
Valuation details
MV $7.95
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 1 of 5
ValuationPrice / book of 1.2×, below the 1.8× median for the 105 Real Estate companies we cover.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$65M over the last 12 months), so there’s no cash-flow value under the price.
ProfitabilityLost $152M over the last 12 months (net income, SEC filings).
Balance sheetNet debt of $2.3B, 123% of the market cap (Sep 30, 2026).
GrowthSales fell 4% over the last 12 months vs the 12 months before (SEC filings).
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%; sales down vs the year-ago quarter; net debt 10.4× EBITDA (limit 3×).
All fundamentals
FCF yield -3.4% · ROE -9% · Sales −4%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −3.4%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 1.28×
- Price / book
- 1.24×
- Market cap
- $1.9Blisted
- Enterprise value
- $4.2B
Growth
- Revenue, 12 months
- $1.5B
- Sales growth, 12 months
- −3.8%vs the 12 months before
- Sales growth, 3 yrs
- +6.2%/yrfrom FY2022
- Diluted EPS, 12 months
- −$0.63
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$152M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- n/anot reported in its SEC filings
- Net margin
- −10.3%
- FCF margin
- −4.4%
- Return on equity
- −9%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $111M
- Total debt
- $2.4B
- Net cash
- −$2.3B
- Debt / equity
- 1.60×
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- −$65M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0.51%$10M paid
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- $3M0.1% of market cap
- Share count, 1 year
- +0.2%diluted shares vs a year ago
- Stock-based comp
- n/anot reported in its SEC filings
Trailing 12 months to Sep 30, 2026; balance sheet at Sep 30, 2026. From Diversified Healthcare Trust of Beneficial Interest’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.1B · Sales −4%
- Free cash flow, 12 months−$0.1B
- Free-cash-flow yield-3.4%
- Gross margin19%
- Operating margin0%
- Return on invested capital0%
- Return on equity−16%
- Sales growth (latest quarter vs year-ago quarter)−4%
- Net debt / EBITDA10.4×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $7.74
- 52-wk lowlowest close, 1 year$4.21−45.6%
- PriceMon Nov 2 close$7.74you are here
- Market Valueavg paid since Aug 3$7.95+2.7%
- 52-wk highhighest close, 1 year$9.64+24.5%
Momentum & 52-week range
RSI 49 · 5 days −0.6%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
DHC is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Diversified Healthcare Trust of Beneficial Interest in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in REITs
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.